SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabin...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!